OncoMatch

OncoMatch/Clinical Trials/NCT07743112

A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

Is NCT07743112 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including MAX-40279 and Azacitidine for acute myeloid leukemia.

Phase 2RecruitingMaxinovel Pty., Ltd.NCT07743112Data as of Sep 2026Location: China

Treatment: MAX-40279 · Azacitidine · VenetoclaxThis is a prospective, multicenter, phase Ⅱ study consisting of dose escalation and ex-pansion stages in unfit newly diagnosed AML.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Targeted therapy

Venetoclax

Chemotherapy

Azacitidine

Other

MAX-40279

Cancer type

Acute Myeloid Leukemia

Biomarker criteria

Excluded: ABL1 bcr-abl1 fusion

Performance status

ECOG 0–3(Limited self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Lab requirements

Blood counts

WBC ≤3×10^9/L

Kidney function

Serum creatinine clearance ≥30 mL/min (measured or calculated); Creatinine clearance ≥30 mL/min but ≤45 mL/min (Cockcroft-Gault)

Liver function

AST/ALT/ALP ≤3×ULN (except: due to leukemic involvement); Total bilirubin ≤1.5×ULN

Cardiac function

History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50%

WBC≤3×10^9/L、AST/ALT/ALP ≤3×ULN (except: due to leukemic involvement)、Total bilirubin ≤1.5×ULN、Serum creatinine clearance ≥30 mL/min (measured or calculated); History of chronic heart failure (CHF) requiring treatment or left ventricular ejection fraction (LVEF) ≤50%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07743112 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Are patients with ABL1 alterations eligible?

No. ABL1 bcr-abl1 fusion is an exclusion criterion.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify